Oleg Nodelman and EcoR1 Disclose Combined 4.8% Holding in KURA

Rhea-AI Filing Summary

EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. and Oleg Nodelman jointly reported beneficial ownership of Kura Oncology common stock on a Schedule 13G/A. EcoR1 and Mr. Nodelman each report shared voting and shared dispositive power over 4,200,000 shares, representing 4.8% of the outstanding common stock, while the Qualified Fund reports shared voting and dispositive power over 3,937,232 shares, representing 4.5%.

The filing states these interests were acquired and are held in the ordinary course of business and were not acquired to influence control of the issuer. The filing also discloses that EcoR1 is the general partner and investment adviser to funds including the Qualified Fund and that Mr. Nodelman is the control person of EcoR1. Percentages are calculated using 86,797,185 shares outstanding as reported in the issuer's quarter-end filing.

Insights

Financial Analyst

TL;DR: Passive institutional disclosure; stakes are material for monitoring but below 5%, suggesting no immediate control intent.

The Schedule 13G/A shows coordinated, transparent disclosure of positions by EcoR1, its Qualified Fund, and Oleg Nodelman. Each reporting person indicates shared voting and dispositive power rather than sole control, and percentages (4.8% and 4.5%) are calculated on an 86.8 million share base from the issuer filing. The certification that holdings are in the ordinary course and not for control reduces immediate governance risk. For investors, this is a signal of institutional interest without an activist control effort.

Corporate Governance Expert

TL;DR: Joint filing with disclaimers limits group inference; governance impact appears limited given stated intent and sub-5% stakes.

The filing explicitly disclaims group membership while filing jointly and records EcoR1 as general partner/adviser and Mr. Nodelman as its control person. Reported positions show no sole voting or dispositive power and the signatories certify the securities were not acquired to influence control. From a governance perspective, the disclosure improves transparency but, based on the facts provided, does not indicate an imminent change in corporate control or board pressure.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Kura Oncology, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

50127T109

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 50127T109

1

Names of Reporting Persons

EcoR1 Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,200,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,200,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,200,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.8 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: Percentage calculated based on 86,797,185 shares of Common Stock outstanding on August 1, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.

SCHEDULE 13G

CUSIP No. 50127T109

1

Names of Reporting Persons

Oleg Nodelman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,200,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,200,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,200,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.8 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Percentage calculated based on 86,797,185 shares of Common Stock outstanding on August 1, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.

SCHEDULE 13G

CUSIP No. 50127T109

1

Names of Reporting Persons

EcoR1 Capital Fund Qualified, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,937,232.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,937,232.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,937,232.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.5 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Percentage calculated based on 86,797,185 shares of Common Stock outstanding on August 1, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Kura Oncology, Inc.
(b)	Address of issuer's principal executive offices: 12730 High Bluff Drive, Suite 400, San Diego, CA 92130
Item 2.
(a)	Name of person filing: EcoR1 Capital, LLC, a Delaware limited liability company ("EcoR1") EcoR1 Capital Fund Qualified, L.P., a Delaware limited partnership ("Qualified Fund") Oleg Nodelman Qualified Fund is filing this statement jointly with the other reporting persons, but not as a member of a group, and it expressly disclaims membership in a group. In addition, the filing of this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any securities covered by this Schedule 13G. Each reporting person also disclaims beneficial ownership of the securities reported herein except to the extent of that person's pecuniary interest therein.
(b)	Address or principal business office or, if none, residence: 357 Tehama Street #3 San Francisco, CA 94103
(c)	Citizenship: See Item 4 of the cover sheet for each reporting person.
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 50127T109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: EcoR1: 4,200,000 Oleg Nodelman: 4,200,000 Qualified Fund: 3,937,232
(b)	Percent of class: EcoR1: 4.8% Oleg Nodelman: 4.8% Qualified Fund: 4.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: EcoR1: 0 Oleg Nodelman: 0 Qualified Fund: 0
	(ii) Shared power to vote or to direct the vote: EcoR1: 4,200,000 Oleg Nodelman: 4,200,000 Qualified Fund: 3,937,232
	(iii) Sole power to dispose or to direct the disposition of: EcoR1: 0 Oleg Nodelman: 0 Qualified Fund: 0
	(iv) Shared power to dispose or to direct the disposition of: EcoR1: 4,200,000 Oleg Nodelman: 4,200,000 Qualified Fund: 3,937,232
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

EcoR1 Capital, LLC

Signature:	/s/ Oleg Nodelman
Name/Title:	Manager
Date:	08/14/2025

Oleg Nodelman

Signature:	/s/ Oleg Nodelman
Name/Title:	Reporting person
Date:	08/14/2025

EcoR1 Capital Fund Qualified, L.P.

Signature:	/s/ Oleg Nodelman
Name/Title:	Manager of the General Partner, EcoR1 Capital, LLC
Date:	08/14/2025

Comments accompanying signature: Exhibit 99.1 -- Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G

Exhibit Information

EXHIBIT 99.1 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

FAQ

What stake did EcoR1 Capital report in KURA?

EcoR1 Capital reported shared voting and dispositive power over 4,200,000 shares, equal to 4.8% of the outstanding common stock.

What stake did EcoR1 Capital Fund Qualified, L.P. report in KURA?

The Qualified Fund reported shared voting and dispositive power over 3,937,232 shares, equal to 4.5% of the outstanding common stock.

Does any reporting person have sole voting or dispositive power?

No. Each reporting person reports 0 shares with sole voting power and sole dispositive power; all reported shares are under shared voting and dispositive power.

Did the filing state an intent to influence control of KURA?

No. The reporting persons certified that the securities were acquired and are held in the ordinary course of business and were not acquired to influence control of the issuer.

What share count was used to calculate the percentages?

Percentages were calculated using 86,797,185 shares of common stock outstanding, as reported in the issuer's quarter-end filing.